ClinicalTrials.gg
Active, not recruitingNCT05581303Updated Oct 27, 2026

Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial

A Phase 3 interventional study of Placebo and Olpasiran in Atherosclerotic Cardiovascular Disease, sponsored by Amgen. Active, not recruiting at 492 sites in 24 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Updated Oct 27, 2026No longer in 10 countries91 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
7,297
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 468 studies in Atherosclerosis with a site in United States — 47 open to participants now, 75 under way, 17 of them phase 3. Atherosclerosis · United States.

Enrollment
23rd of 328
7,297 · median 119
Started
2022
with 11 others
Phase 3
61 of 468
6 open now
Primary completion
2028-03
later than 46 of 70 live
Registered
406th of 468
by date

Among the 468 studies in Atherosclerosis with a site in United States, this one is the 23rd largest by enrollment of the 328 interventional ones that give a count, is one of 12 that started in 2022, is one of 61 in phase 3, reaches primary completion later than 46 of the 70 other live ones, and was the 406th registered.

Atherosclerosis

1,519 studies on the registry are indexed under Atherosclerosis; 226 are open to participants now.

Browse Atherosclerosis studies →

Open to participants now

47 of the 468 studies in Atherosclerosis with a site in United States are open now. Recruiting first, the newest first:

42 more — sign in →

All 47 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 163 Atherosclerosis studies recruiting now, 85 (52%) set no upper age limit and 34 (21%) stop at 75 or younger; 16 take children under 18; 35 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 468 studies in Atherosclerosis with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this trial is to compare the effect of treatment with olpasiran, to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants with atherosclerotic cardiovascular disease (ASCVD) and elevated Lipoprotein(a).

03

Conditions studied

  • Atherosclerotic Cardiovascular Disease

Browse trials for

Keywords

  • Atherosclerotic Cardiovascular Disease
  • ASCVD
  • AMG 890
  • Olpasiran
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to ≤ 85 years
  • Lp(a) ≥ 200 nmol/L during screening
  • History of ASCVD as evidenced by history of either:

    • Myocardial infarction (presumed type 1 event due to plaque rupture/erosion) and/or
    • Coronary revascularization with percutaneous coronary intervention AND at least 1 additional risk factor.

Exclusion criteria

Exclusion Criteria:

  • Severe renal dysfunction
  • (AST) or alanine aminotransferase (ALT) > 3 x (ULN), or total (TBL) > 2 x ULN during screening
  • History of hemorrhagic stroke
  • History of major bleeding disorder
  • Planned cardiac surgery or arterial revascularization
  • Severe heart failure
  • Current, recent, or planned lipoprotein apheresis
  • Previously received ribonucleic acid therapy specifically targeting Lp(a)
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
7,297 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Placebo will be administered by subcutaneous injection.

    Drug: Placebo

  • Experimental
    Olpasiran

    Olpasiran will be administered by subcutaneous injection.

    Drug: Olpasiran

Interventions

  • DrugPlacebo

    Placebo given by subcutaneous injection once every 12 weeks (Q12W).

  • Olpasiran given by subcutaneous injection Q12W.

06

What researchers measure

Primary outcomes

  1. Time to CHD death, myocardial infarction, or urgent coronary revascularization, whichever occurs first

    Time frame: Approximately 5 years

Secondary outcomes

  1. Time to cardiovascular death, myocardial infarction, or ischemic stroke, whichever occurs first

    Time frame: Approximately 5 years

  2. Time to cardiovascular death, myocardial infarction, urgent coronary revascularization, or ischemic stroke, whichever occurs first

    Time frame: Approximately 5 years

  3. Percent change from baseline to Week 48 in Lipoprotein(a)

    Time frame: Baseline and Week 48

  4. Time to myocardial infarction

    Time frame: Approximately 5 years

  5. Time to CHD death or myocardial infarction, whichever occurs first

    Time frame: Approximately 5 years

  6. Time to urgent coronary revascularization

    Time frame: Approximately 5 years

  7. Time to coronary revascularization

    Time frame: Approximately 5 years

  8. Time to CHD death

    Time frame: Approximately 5 years

  9. Time to cardiovascular death

    Time frame: Approximately 5 years

  10. Time to death by any cause

    Time frame: Approximately 5 years

  11. Time to ischemic stroke

    Time frame: Approximately 5 years

07

Study locations

492 sites

Showing the first 100 of 492 sites across 24 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Procyk G, Tyrna P, Mlynarczuk-Bialy I, Budzianowski J, Olasinska-Wisniewska A, Kochman J, Gasecka A. Lipoprotein(a) and clinical outcomes after transcatheter aortic valve implantation: a prospective, multicenter cohort study. Pol Arch Intern Med. 2026 Apr 29;136(4):17253. doi: 10.20452/pamw.17253. Epub 2026 Mar 17. PubMed 41841810 ↗
  • Byambaa E, Roshanravan B, Berglund L. Lipoprotein(a) and CKD: Insights into New Therapeutic Opportunities. Clin J Am Soc Nephrol. 2026 Aug 1;21(8):1469-1481. doi: 10.2215/CJN.0000000968. Epub 2025 Dec 2. PubMed 41329869 ↗
  • Nicholls SJ, Nelson AJ, Michael LF. Oral agents for lowering lipoprotein(a). Curr Opin Lipidol. 2024 Dec 1;35(6):275-280. doi: 10.1097/MOL.0000000000000953. Epub 2024 Sep 25. PubMed 39329200 ↗
  • Burvill A, Watts GF, Norman R, Ademi Z. Early health technology assessment of gene silencing therapies for lowering lipoprotein(a) in the secondary prevention of coronary heart disease. J Clin Lipidol. 2024 Nov-Dec;18(6):e946-e956. doi: 10.1016/j.jacl.2024.08.012. Epub 2024 Aug 31. PubMed 39322524 ↗
  • Dimitriadis K, Theofilis P, Iliakis P, Pyrpyris N, Dri E, Sakalidis A, Soulaidopoulos S, Tsioufis P, Fragkoulis C, Chrysohoou C, Tsiachris D, Tsioufis K. Management of dyslipidemia in coronary artery disease: the present and the future. Coron Artery Dis. 2024 Sep 1;35(6):516-524. doi: 10.1097/MCA.0000000000001375. Epub 2024 Apr 29. PubMed 38682459 ↗
  • Karp A, Jacobs M, Barris B, Labkowsky A, Frishman WH. Lipoprotein(a): A Review of Risk Factors, Measurements, and Novel Treatment Modalities. Cardiol Rev. 2025 Jul-Aug 01;33(4):352-358. doi: 10.1097/CRD.0000000000000667. Epub 2024 Feb 28. PubMed 38415744 ↗

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this trial will be considered beginning 18 months after the trial has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this trial.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen trial/trials in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.

Data sharing details ↗ · www.amgen.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Mar 2028, 63 months after the start.

Of 36 industry-sponsored phase 3 interventional studies under Atherosclerosis, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 51. This study's planned 63 months is above that.

Counting every sponsor, half of 53 studies reached it within 35 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 12, 2022
First posted
Oct 14, 2022
StartActual
Dec 14, 2022
Primary completionEst.
Mar 31, 2028
CompletionEst.
Mar 31, 2028
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
91 sites added, 336 sites removed; no longer in Argentina, Belgium, Canada, Denmark, Lithuania and 5 more
All 10 countries

Argentina, Belgium, Canada, Denmark, Lithuania, Netherlands, Portugal, Romania, Slovakia, United Kingdom

Show 91 added (22 United States, 11 China, 10 Brazil, 8 Taiwan, 7 Australia, 5 Poland, 4 France, 4 Japan, 4 Spain, 3 Hungary, 3 Italy, 3 Mexico, 2 Bulgaria, 2 Hong Kong, 1 Czechia, 1 Germany, 1 Greece)
  • University of Alabama Saint Vincent's Birmingham · Birmingham, United States
  • Huntsville Clinical Research, LLC · Huntsville, United States
  • HonorHealth Research and Innovation Institute · Phoenix, United States
  • Pacific Oaks Medical Group · Beverly Hills, United States
  • Excel Medical Clinical Trials · Miami, United States
  • Nsc Research · Johns Creek, United States
  • St Lukes Idaho · Meridian, United States
  • Endeavor Health-Northwest Community Healthcare · Arlington Heights, United States
  • Endeavor Health Skokie Hospital · Evanston, United States
  • Louisiana Heart Center · Covington, United States
  • Ascension Saint Agnes Heart Care · Baltimore, United States
  • Johns Hopkins University · Baltimore, United States
  • Henry Ford Health System · Detroit, United States
  • Advanced Cardiology Associates · Rochester Hills, United States
  • Healthy Heart Cardiology · Rochester Hills, United States
  • Fairview Health Services M Health Fairview St Johns Hospital · Maplewood, United States
  • Mayo Clinic · Rochester, United States
  • New York University Grossman School of Medicine and New York University Langone Hospitals · New York, United States
  • WMCHealth Heart and Vascular Institute Kingston Division of Cardiology · Valhalla, United States
  • White Plains Hospital Physician Associates - Hudson Valley Cardiovascular Group · Yorktown Heights, United States
  • Virginia Heart - Loudoun · Falls Church, United States
  • Virginia Heart · Leesburg, United States
  • Momentum Clinical Research - Darlinghurst · Sydney, Australia
  • Nightingale Research · Adelaide, Australia
  • Flinders Medical Centre · Bedford Park, Australia
  • Advara HeartCare Leabrook · Leabrook, Australia
  • Clinitrials - West Perth · Perth, Australia
  • Advara HeartCare Joondalup · Joondalup, Australia
  • Linear Clinical Research Limited · Nedlands, Australia
  • Hospital Universitario Walter Cantidio - Universidade Federal do Ceara · Fortaleza, Brazil
  • …and 61 more on the registry record
Show 336 removed
  • Ascension Saint Vincents Birmingham · Birmingham, United States
  • Heart Center Research LLC · Huntsville, United States
  • Alaska Cardiovascular Research Foundation · Anchorage, United States
  • HonorHealth Research and Innovation Institute · Scottsdale, United States
  • Vitality Clinical Research · Beverly Hills, United States
  • Excel Medical Clinical Trials · Boca Raton, United States
  • Care Access - Tampa · Tampa, United States
  • NSC Research · Johns Creek, United States
  • St Lukes Idaho Cardiology Associates · Meridian, United States
  • Northwest Heart Clinical Research LLC · Arlington Heights, United States
  • Northshore University Health System · Evanston, United States
  • University of Louisville Health - Jewish Hospital · Louisville, United States
  • Louisiana Heart Center · Hammond, United States
  • Care Access - Lake Charles · Lake Charles, United States
  • Maryland Cardiovascular Specialists · Baltimore, United States
  • Johns Hopkins University School of Medicine · Baltimore, United States
  • Henry Ford Hospital · Detroit, United States
  • Ascension Saint John Hospital · Detroit, United States
  • Advanced Cardiology Associates · Grand Rapids, United States
  • Healthy Heart Cardiology · Grand Rapids, United States
  • Fairview Health Services · Maplewood, United States
  • Mayo Clinic Rochester · Rochester, United States
  • New York Presbyterian Medical Group Hudson Valley Cardiology · Cortlandt Manor, United States
  • Elligo Health Research · Kew Gardens, United States
  • WMCHealth Heart and Vascular Institute Kingston Division of Cardiology · Kingston, United States
  • New York University Langone Health · New York, United States
  • Icahn School of Medicine at Mount Sinai Queens · New York, United States
  • Westchester Medical Center · Valhalla, United States
  • NY Family Docs · Woodhaven, United States
  • Lapis Clinical Research · Mooresville, United States
  • …and 306 more on the registry record
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    91 sites added, 336 sites removed; no longer in Argentina, Belgium, Canada, Denmark, Lithuania and 5 more
    All 10 countries

    Argentina, Belgium, Canada, Denmark, Lithuania, Netherlands, Portugal, Romania, Slovakia, United Kingdom

    Show 91 added (22 United States, 11 China, 10 Brazil, 8 Taiwan, 7 Australia, 5 Poland, 4 France, 4 Japan, 4 Spain, 3 Hungary, 3 Italy, 3 Mexico, 2 Bulgaria, 2 Hong Kong, 1 Czechia, 1 Germany, 1 Greece)
    • University of Alabama Saint Vincent's Birmingham · Birmingham, United States
    • Huntsville Clinical Research, LLC · Huntsville, United States
    • HonorHealth Research and Innovation Institute · Phoenix, United States
    • Pacific Oaks Medical Group · Beverly Hills, United States
    • Excel Medical Clinical Trials · Miami, United States
    • Nsc Research · Johns Creek, United States
    • St Lukes Idaho · Meridian, United States
    • Endeavor Health-Northwest Community Healthcare · Arlington Heights, United States
    • Endeavor Health Skokie Hospital · Evanston, United States
    • Louisiana Heart Center · Covington, United States
    • Ascension Saint Agnes Heart Care · Baltimore, United States
    • Johns Hopkins University · Baltimore, United States
    • Henry Ford Health System · Detroit, United States
    • Advanced Cardiology Associates · Rochester Hills, United States
    • Healthy Heart Cardiology · Rochester Hills, United States
    • Fairview Health Services M Health Fairview St Johns Hospital · Maplewood, United States
    • Mayo Clinic · Rochester, United States
    • New York University Grossman School of Medicine and New York University Langone Hospitals · New York, United States
    • WMCHealth Heart and Vascular Institute Kingston Division of Cardiology · Valhalla, United States
    • White Plains Hospital Physician Associates - Hudson Valley Cardiovascular Group · Yorktown Heights, United States
    • Virginia Heart - Loudoun · Falls Church, United States
    • Virginia Heart · Leesburg, United States
    • Momentum Clinical Research - Darlinghurst · Sydney, Australia
    • Nightingale Research · Adelaide, Australia
    • Flinders Medical Centre · Bedford Park, Australia
    • Advara HeartCare Leabrook · Leabrook, Australia
    • Clinitrials - West Perth · Perth, Australia
    • Advara HeartCare Joondalup · Joondalup, Australia
    • Linear Clinical Research Limited · Nedlands, Australia
    • Hospital Universitario Walter Cantidio - Universidade Federal do Ceara · Fortaleza, Brazil
    • …and 61 more on the registry record
    Show 336 removed
    • Ascension Saint Vincents Birmingham · Birmingham, United States
    • Heart Center Research LLC · Huntsville, United States
    • Alaska Cardiovascular Research Foundation · Anchorage, United States
    • HonorHealth Research and Innovation Institute · Scottsdale, United States
    • Vitality Clinical Research · Beverly Hills, United States
    • Excel Medical Clinical Trials · Boca Raton, United States
    • Care Access - Tampa · Tampa, United States
    • NSC Research · Johns Creek, United States
    • St Lukes Idaho Cardiology Associates · Meridian, United States
    • Northwest Heart Clinical Research LLC · Arlington Heights, United States
    • Northshore University Health System · Evanston, United States
    • University of Louisville Health - Jewish Hospital · Louisville, United States
    • Louisiana Heart Center · Hammond, United States
    • Care Access - Lake Charles · Lake Charles, United States
    • Maryland Cardiovascular Specialists · Baltimore, United States
    • Johns Hopkins University School of Medicine · Baltimore, United States
    • Henry Ford Hospital · Detroit, United States
    • Ascension Saint John Hospital · Detroit, United States
    • Advanced Cardiology Associates · Grand Rapids, United States
    • Healthy Heart Cardiology · Grand Rapids, United States
    • Fairview Health Services · Maplewood, United States
    • Mayo Clinic Rochester · Rochester, United States
    • New York Presbyterian Medical Group Hudson Valley Cardiology · Cortlandt Manor, United States
    • Elligo Health Research · Kew Gardens, United States
    • WMCHealth Heart and Vascular Institute Kingston Division of Cardiology · Kingston, United States
    • New York University Langone Health · New York, United States
    • Icahn School of Medicine at Mount Sinai Queens · New York, United States
    • Westchester Medical Center · Valhalla, United States
    • NY Family Docs · Woodhaven, United States
    • Lapis Clinical Research · Mooresville, United States
    • …and 306 more on the registry record
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05581303
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 14, 2022
Start date
Dec 14, 2022
Primary completion
Mar 31, 2028 (estimated)
Completion
Mar 31, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olpasiran

Start the discussion